Pliant Therapeutics Appoints New CMO and CSO
Ticker: PLRX · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: PLRX
TL;DR
Pliant Therapeutics shuffles top medical and science execs, bringing in Dr. Weitz as CMO and Dr. Lee as CSO.
AI Summary
Pliant Therapeutics, Inc. announced on December 2, 2025, the appointment of Dr. David J. Weitz as Chief Medical Officer and Dr. David M. Lee as Chief Scientific Officer. The company also reported the departure of Dr. David M. Lee from his role as Chief Medical Officer. These changes are effective immediately.
Why It Matters
The appointment of new leadership in key scientific and medical roles suggests a strategic shift or expansion in Pliant Therapeutics' research and development efforts.
Risk Assessment
Risk Level: medium — Changes in key executive positions can indicate internal shifts or challenges within the company, impacting strategic direction and execution.
Key Players & Entities
- Pliant Therapeutics, Inc. (company) — Registrant
- Dr. David J. Weitz (person) — Appointed Chief Medical Officer
- Dr. David M. Lee (person) — Appointed Chief Scientific Officer and former Chief Medical Officer
- December 2, 2025 (date) — Effective date of appointments and departure
FAQ
Who has been appointed as the new Chief Medical Officer at Pliant Therapeutics?
Dr. David J. Weitz has been appointed as the new Chief Medical Officer.
What is Dr. David M. Lee's new role at Pliant Therapeutics?
Dr. David M. Lee has been appointed as the Chief Scientific Officer.
What was Dr. David M. Lee's previous role at Pliant Therapeutics?
Dr. David M. Lee was previously the Chief Medical Officer.
When were these executive changes effective?
The changes were effective as of December 2, 2025.
What is the exact name of the company filing this report?
The exact name of the company is PLIANT THERAPEUTICS, INC.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2025-12-08 16:41:42
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Market
Filing Documents
- plrx-20251202.htm (8-K) — 26KB
- 0001746473-25-000179.txt ( ) — 186KB
- plrx-20251202.xsd (EX-101.SCH) — 3KB
- plrx-20251202_def.xml (EX-101.DEF) — 16KB
- plrx-20251202_lab.xml (EX-101.LAB) — 29KB
- plrx-20251202_pre.xml (EX-101.PRE) — 17KB
- plrx-20251202_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: December 8, 2025 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer